Here's what we'll cover
Here's what we'll cover
On August 28, 2026, the FDA approved a new use for Mounjaro (tirzepatide): lowering the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes who are at high risk for those events. MACE means cardiovascular death, nonfatal heart attack, or nonfatal stroke.
The approval matters, but the trial behind it was designed differently from most heart outcome studies, and that detail changes how you should read the headline.
What the New Indication Says
Mounjaro was first approved in 2022 to improve blood sugar control in adults with type 2 diabetes, and that use now extends to children 10 and older. The new indication adds a second label claim: reducing MACE in adults with type 2 diabetes at high cardiovascular risk, according to Pharmacy Times.
The approval applies to Mounjaro. Zepbound contains the same active ingredient but is approved for weight management and obstructive sleep apnea, and it did not receive this cardiovascular indication.
Inside the SURPASS CVOT Trial
Most cardiovascular outcome trials compare a drug against placebo. SURPASS CVOT compared tirzepatide head to head against dulaglutide (Trulicity), a GLP-1 medication that already has proven cardiovascular benefit.
| Trial detail | SURPASS CVOT |
|---|---|
| Participants | 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease |
| Comparison | Tirzepatide up to 15 mg weekly vs dulaglutide 1.5 mg weekly |
| Median follow up | About 4 years (210 weeks) |
| MACE rate | 12.2% tirzepatide vs 13.1% dulaglutide |
| MACE hazard ratio | 0.92 (95% CI 0.83 to 1.01) |
| Result | Noninferior to dulaglutide; superiority not shown |
In plain terms, tirzepatide protected the heart at least as well as a drug already known to reduce cardiovascular events. The 8% lower event rate was not large enough to prove tirzepatide is better on that main measure, as TCTMD reported when the results were published in the New England Journal of Medicine.
Several secondary findings favored tirzepatide. Deaths from any cause were lower, with a hazard ratio of 0.84 (95% CI 0.75 to 0.94), according to Healio. Participants on tirzepatide lost about 11.6% of body weight versus 4.5% on dulaglutide, and HbA1c fell further. More people stopped tirzepatide because of side effects, 13.2% versus 10.1%, mostly due to digestive symptoms.
Who This Approval Is Most Relevant For
Adults With Type 2 Diabetes and Heart Disease
If you have type 2 diabetes plus a history of heart attack, stroke, coronary artery disease, or peripheral artery disease, you match the population studied. Your doctor now has an FDA approved option that addresses blood sugar, weight, and cardiovascular risk together.
Adults With Type 2 Diabetes and Several Risk Factors
The label covers adults at high cardiovascular risk. Whether you qualify depends on your history, including blood pressure, cholesterol, kidney function, and smoking. Ask your clinician how they interpret high risk for you.
People Facing Coverage Hurdles
A formal cardiovascular indication gives prescribers another documented reason for Mounjaro when a plan requires prior authorization. It does not guarantee coverage.
How Mounjaro Compares to Other GLP-1 Options
| Medication | Active ingredient | Cardiovascular indication | Key trial |
|---|---|---|---|
| Mounjaro | Tirzepatide | Yes, MACE reduction in type 2 diabetes at high risk | SURPASS CVOT (vs dulaglutide) |
| Ozempic | Semaglutide | Yes, MACE reduction in type 2 diabetes with heart disease | SUSTAIN 6 (vs placebo) |
| Victoza | Liraglutide | Yes, MACE reduction in type 2 diabetes with heart disease | LEADER (vs placebo) |
| Trulicity | Dulaglutide | Yes, MACE reduction in type 2 diabetes | REWIND (vs placebo) |
| Wegovy | Semaglutide 2.4 mg | Yes, MACE reduction in adults with heart disease and obesity or overweight | SELECT (vs placebo) |
Earlier approvals came from placebo controlled trials such as SUSTAIN 6, LEADER, and SELECT. Mounjaro's approval rests on matching an active drug that already works, which is a tougher comparison but a different kind of evidence.
Tirzepatide's dual GIP and GLP-1 mechanism also produced more weight loss and HbA1c reduction than dulaglutide in the trial, which may matter if those are major goals for you.
What This Could Mean for Insurance
Insurers often tie coverage to FDA indications and diagnosis codes. Prescribers can now document cardiovascular risk reduction alongside glycemic control when submitting a prior authorization for Mounjaro. Medicare Part D plans already cover Mounjaro for type 2 diabetes, subject to each plan's rules.
If you are paying out of pocket or waiting on approval, compare current GLP-1 coupons and savings programs.
Questions to Ask Your Doctor
- Do I meet the high cardiovascular risk criteria in the new Mounjaro indication?
- How does tirzepatide compare with my current GLP-1 for my heart, weight, and blood sugar goals?
- Would switching be worth the higher chance of digestive side effects?
- Can you document the cardiovascular indication to support a prior authorization?
- Do any of my other medications, such as insulin or a sulfonylurea, need adjusting?
No waiting list. No insurance needed.
Frequently Asked Questions
What did the FDA approve for Mounjaro in 2026?
On August 28, 2026, the FDA approved Mounjaro to lower the risk of major adverse cardiovascular events, meaning cardiovascular death, nonfatal heart attack, or nonfatal stroke, in adults with type 2 diabetes who are at high risk for these events.
Was Mounjaro better than other GLP-1 drugs at preventing heart attacks?
Not proven. SURPASS CVOT compared tirzepatide with dulaglutide and found it noninferior, with an 8% lower MACE rate that did not reach statistical significance for superiority. Deaths from any cause were lower with tirzepatide.
Does the new heart indication apply to Zepbound?
No. The cardiovascular indication was approved for Mounjaro in adults with type 2 diabetes. Zepbound contains the same active ingredient but is approved for weight management and obstructive sleep apnea.
Who was studied in SURPASS CVOT?
The trial enrolled 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease, such as prior heart attack, stroke, or artery disease, and followed them for a median of about four years.
Will insurance cover Mounjaro for heart risk now?
A cardiovascular indication can strengthen a prior authorization request, but coverage still depends on your plan. Ask your prescriber to document both glycemic control and cardiovascular risk reduction.
Should I switch from Ozempic to Mounjaro for heart protection?
Both have FDA cardiovascular indications in type 2 diabetes. Switching may make sense for more weight loss or blood sugar control, but discuss tolerability, cost, and coverage with your doctor first.
The Bottom Line
Mounjaro is now FDA approved to lower the risk of heart attack, stroke, and cardiovascular death in adults with type 2 diabetes at high cardiovascular risk. SURPASS CVOT showed it is at least as protective as dulaglutide, with fewer deaths from any cause, more weight loss, and better blood sugar control, though it did not prove superiority on the main heart outcome.
If you already take Mounjaro, nothing changes about how you use it. If you have type 2 diabetes and heart disease, this approval is a good reason to review your options with your doctor, including whether Ozempic, Mounjaro, or another GLP-1 best fits your goals. If you have heart disease and obesity without diabetes, Wegovy remains the GLP-1 with a cardiovascular indication for that group.
To find a prescriber experienced with GLP-1 and cardiometabolic care, compare vetted telehealth providers. Always consult a licensed clinician before changing your medications.